<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03630328</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00008009</org_study_id>
    <nct_id>NCT03630328</nct_id>
  </id_info>
  <brief_title>Angelica Gigas Dietary Supplements and Human Immune Cells</brief_title>
  <official_title>Study of Angelica Gigas Dietary Supplements (Cogni.Q) and Potential Effects on Human Immune Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Milton S. Hershey Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Milton S. Hershey Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This human study will test the impact of dietary supplement vegicaps containing Korean
      Angelica root extract on 2 types of human immune cells: neutrophils that kill bacteria and
      other germs and natural killer (NK) cells that kill virus-infected cells and cancers. The
      investigators had done an earlier study with Korean Angelica supplement and discovered even a
      single dose of it increased blood neutrophils and NK cells within 24 h. In the new study,
      Korean Angelica capsules (Cogni.Q) will be compared head-to-head with dummy (placebo)
      capsules. This is to make sure the immune boosting actions are really from the Korean
      Angelica supplement.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 6, 2019</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neutrophil counts and NK cell counts in peripheral blood</measure>
    <time_frame>70 days</time_frame>
    <description>Using CBC diff to measure neutrophil counts, NK cells number will be enumerated using flowcytometer</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>T cells in peripheral blood,</measure>
    <time_frame>70 days</time_frame>
    <description>T cells number will be enumerated using flowcytometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of pyranocoumarins, androgens, and inflammatory/anti-inflammatory cytokines.</measure>
    <time_frame>70 days</time_frame>
    <description>Determine Plasma concentrations of pyranocoumarins (as compliance marker), androgens, and inflammatory/anti-inflammatory cytokines.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid profiling</measure>
    <time_frame>70 days</time_frame>
    <description>blood test will be done at every visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NK mRNA signature</measure>
    <time_frame>70 days</time_frame>
    <description>NK mRNA signature by RNA-seq transcriptomics using RNA prepared from Pax Gene tube-preserved whole blood collected on each visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PBMC isolation for testing NK activity</measure>
    <time_frame>70 days</time_frame>
    <description>PBMCs will be isolated at every blood draw and kept frozen. They will be used to determine NK cell activity in future.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CMP-EGFR</measure>
    <time_frame>70 days</time_frame>
    <description>blood test will be done at every visit</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Innate Immune Cells</condition>
  <arm_group>
    <arm_group_label>Cogni.Q</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>800 mg per day (Two 200 mg capsules in the morning and two 200 mg capsules in the evening) for 21 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two capsules in the morning and two capsules in the evening for 21 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Cogni.Q</intervention_name>
    <description>AGN</description>
    <arm_group_label>Cogni.Q</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Cogni.Q</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects weighing between 110 to 240 pounds; their body mass index (BMI) should be in
             the range of 19 to 30

          -  Subjects having normal hepatic, renal function as assessed by history, physical and
             clinical chemistry analysis (CMP eGFR, see supporting document for normal reference
             ranges).

          -  Subjects with normal blood pressure (systolic below 120 mm Hg and diastolic below 80
             mm Hg)

        Exclusion Criteria:

          -  Subjects positive for HIV, HBV and HCV (self-reported)

          -  Subjects taking any kind of prescription medications regularly or within 10 days of
             the study will be excluded. Therefore, subjects with diabetes, major cardiovascular
             diseases, cancer, severe hypertension, severe hepatic cirrhosis or cirrhosis of the
             liver, and kidney disease (self-reported) will be excluded.

          -  Subjects using tobacco products, nicotine patches and excessive alcohol

          -  Subjects taking dietary or herbal supplements that contain AGN (e.g. Cogni.Q,
             Decursinol-50, Ache Action, Fast-Acting Joint Formula, EstroG-100/Profemin) within 10
             days of the study.

          -  Non-English-speaking subjects
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Junxuan Lu, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Penn State College of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Deepkamal N Karelia, Ph.D.</last_name>
    <phone>717-531-0003</phone>
    <phone_ext>285476</phone_ext>
    <email>dkarelia@pennstatehealth.psu.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Penn State College of Medicine</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deepkamal N Karelia, Ph.D.</last_name>
    </contact>
    <investigator>
      <last_name>Junxuan Lu, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>August 9, 2018</study_first_submitted>
  <study_first_submitted_qc>August 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2018</study_first_posted>
  <last_update_submitted>March 4, 2020</last_update_submitted>
  <last_update_submitted_qc>March 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Milton S. Hershey Medical Center</investigator_affiliation>
    <investigator_full_name>Junxuan Lu</investigator_full_name>
    <investigator_title>Professor of Pharmacology</investigator_title>
  </responsible_party>
  <keyword>Cogni.Q</keyword>
  <keyword>immune enhancement</keyword>
  <keyword>natural killer cells</keyword>
  <keyword>NK cells</keyword>
  <keyword>Korean Angelica gigas</keyword>
  <keyword>AGN</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 18, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/28/NCT03630328/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

